

Claim 24: The method of claim 23, wherein said mammalian IL-TIF/IL-21 is human IL-TIF/IL-21.

Claim 25: The method of claim 24, wherein said human IL-TIF/IL-21 is encoded by SEQ ID NO: 25 or 26.

Claim 26: The method of claim 22, wherein said cell is a human cell.

Claim 27: The method of claim 22, further comprising inducing production of an acute phase protein, production of which is regulated by STAT 3 transcription factor.

Claim 28: The method of claim 26, wherein said cell is a liver cell.

Claim 29: The method of claim 27, wherein said acute phase protein is human serum amyloid A, *1 chymotrypsin, or haptoglobin.

Claim 30: The method of claim 24, wherein said human IL-TIF/IL-21 also stimulates expression of STAT 1 transcription factor.

Claim 31: The method of claim 24, wherein said mammalian IL-TIF/IL-21 is murine IL-TIF/IL-21.


Claim 32: The method of claim 31, wherein said murine IL-TIF/IL-21 also stimulates expression of STAT 5 transcription factor.

REMARKS

Entry of the amendment is requested.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.


Norman D. Hanson, Esq.
Registration No. 30,946